An innovative service company focusing on the field of drug quality control

News

Contact Us

You are here:Home >> News >> Company News

Company News

Baricitinib —— the solution to the problem of hair loss.

Time:2024-08-19 Views:17

  Nothing is easy  in this world, except getting old and fat and--

  Baldness!

 

  With the accelerated pace of modern life and the increasing pressure of modern people‘s work, more and more people are falling into the trouble of hair loss. Daily loss of 50-100 hair is normal, mostly ordinary metabolism. However, if the daily hair loss exceeds this amount and has a tendency to increase gradually, it is necessary to pay extra attention to it. alopecia areata is one of the more notable and specific symptoms, which is characterized by the sudden appearance of patches of hair loss, usually with distinct borders.

  Alopecia Areata has a great impact on the patient‘s appearance and mental health, and its treatment aims to control the progress of the disease, promote hair regrowth, prevent or reduce recurrence, and improve the patient‘s quality of life.According to the International Journal of Dermatology and Venereology, there are approximately 147 million patients with Alopecia Areata worldwide. Currently, the systemic treatment drugs for adult severe Alopecia Areatas include Baricitinib, the first JAK inhibitor approved for the treatment of severe Alopecia Areata in the world.On March 27, 2023,Baricitinib tablets were formally approved in China for the systemic treatment of adult severe Alopecia Areata, which is the first innovative targeted drug for the systemic treatment of severe Alopecia Areata in China.

 Jerry Shapiro said in WCD 2023 Oral Presentation. that for patients with a shorter course of Alopecia Areata, regardless of severity, the proportion of patients who get a clinical response after treatment with Baricitinib is higher than that of long-term patients. Early intervention can benefit more adults with severe Alopecia Areata with baricitinib.

 

Currently, the research on Baricitinib is ongoing,SZEB supplies Baricitinib impurity  to help the research better, the following is part of its catalog.


 

 We also have 50,000+ impurity , our own brand impurity controls have been out of 100,000+, advanced scientific research strength, perfect supply chain services, for more impurity information, you can go to the official website to view: www.bio-tech.com

  • Previous:New impurity | Canagliflozin impurity 8  2024/09/12
  • Next:Drug Impurity ——glycoconjugate  2024/08/14